Clinical Trial Update: Clinical Study of Novel CAR-ITNK Cells Targeting CD70 and CLL1 for Refractory/Relapsed AML [EARLY_Phase 1]

View source ↗

Summary

A first-in-human early-phase trial of CAR-ITNK cells targeting CD70 and CLL1 for refractory/relapsed acute myeloid leukemia, not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CAR-ITNK cells targeting CD70 and CLL1

Snippet

Sponsor: Tongji Hospital | Conditions: R/R AML | EARLY_Phase 1 | Status: NOT_YET_RECRUITING